FLAURA2 Results Demonstrate Osimertinib Plus Chemotherapy Superior Compared to Osimertinib Alone

Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news